Skin Cancer

PEPOO5 Topical trials initiated in non-melanoma skin cancer, actinic keratosis

Published in Drug Week, October 1st, 2004

Peplin Biotech Ltd (PEP) announced that its corporate partner, Allergan, Inc., (AGN) has initiated clinical trials of its lead product PEP005 Topical.

Allergan, under license from Peplin, is developing PEP005 Topical to treat non-melanoma skin cancer (NMSC) and actinic keratosis (AK). The first patients have now been enrolled and treated.

These trials are being conducted under investigational new drug (IND) applications, which were filed by Allergan with the U.S. Food and Drug Administration (FDA) in June.

This milestone marks the start of a comprehensive program of phase I-II studies, which will be conducted in the U.S. and in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-10-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry